These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19066384)

  • 1. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.
    Kato GJ; Gladwin MT
    JAMA; 2008 Dec; 300(22):2638-46. PubMed ID: 19066384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle cell disease at the dawn of the molecular era.
    Abboud MR; Musallam KM
    Hemoglobin; 2009; 33 Suppl 1():S93-S106. PubMed ID: 20001639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite, and apolipoprotein A-I.
    Kato GJ
    Hematology Am Soc Hematol Educ Program; 2008; ():186-92. PubMed ID: 19074079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.
    Kato GJ; McGowan V; Machado RF; Little JA; Taylor J; Morris CR; Nichols JS; Wang X; Poljakovic M; Morris SM; Gladwin MT
    Blood; 2006 Mar; 107(6):2279-85. PubMed ID: 16291595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.
    Kato GJ; Hebbel RP; Steinberg MH; Gladwin MT
    Am J Hematol; 2009 Sep; 84(9):618-25. PubMed ID: 19610078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravascular hemolysis and the pathophysiology of sickle cell disease.
    Kato GJ; Steinberg MH; Gladwin MT
    J Clin Invest; 2017 Mar; 127(3):750-760. PubMed ID: 28248201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of vasculopathy in sickle cell disease and thalassemia.
    Morris CR
    Hematology Am Soc Hematol Educ Program; 2008; ():177-85. PubMed ID: 19074078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.
    Hsu LL; Champion HC; Campbell-Lee SA; Bivalacqua TJ; Manci EA; Diwan BA; Schimel DM; Cochard AE; Wang X; Schechter AN; Noguchi CT; Gladwin MT
    Blood; 2007 Apr; 109(7):3088-98. PubMed ID: 17158223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasculopathy and pulmonary hypertension in sickle cell disease.
    Potoka KP; Gladwin MT
    Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L314-24. PubMed ID: 25398989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial dysfunction in Sickle Cell Disease: Strategies for the treatment.
    Pavan AR; Terroni B; Dos Santos JL
    Nitric Oxide; 2024 Aug; 149():7-17. PubMed ID: 38806107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.
    Morris CR; Kato GJ; Poljakovic M; Wang X; Blackwelder WC; Sachdev V; Hazen SL; Vichinsky EP; Morris SM; Gladwin MT
    JAMA; 2005 Jul; 294(1):81-90. PubMed ID: 15998894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.
    Kato GJ; Gladwin MT; Steinberg MH
    Blood Rev; 2007 Jan; 21(1):37-47. PubMed ID: 17084951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.
    Villagra J; Shiva S; Hunter LA; Machado RF; Gladwin MT; Kato GJ
    Blood; 2007 Sep; 110(6):2166-72. PubMed ID: 17536019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sickle cell disease vasculopathy: a state of nitric oxide resistance.
    Wood KC; Hsu LL; Gladwin MT
    Free Radic Biol Med; 2008 Apr; 44(8):1506-28. PubMed ID: 18261470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degree of anemia, indirect markers of hemolysis, and vascular complications of sickle cell disease in Africa.
    Dubert M; Elion J; Tolo A; Diallo DA; Diop S; Diagne I; Sanogo I; Belinga S; Guifo O; Wamba G; Ngo Sack F; Boidy K; Kamara I; Traore Y; Diakite CO; Gbonon V; Faye BF; Seck M; Deme Ly I; Chelo D; N'Guetta R; Diop IB; Gaye B; Jouven X; Ranque B
    Blood; 2017 Nov; 130(20):2215-2223. PubMed ID: 28931524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary hypertension and nitric oxide depletion in sickle cell disease.
    Bunn HF; Nathan DG; Dover GJ; Hebbel RP; Platt OS; Rosse WF; Ware RE
    Blood; 2010 Aug; 116(5):687-92. PubMed ID: 20395414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular complications of sickle cell disease.
    Usmani A; Machado RF
    Clin Hemorheol Microcirc; 2018; 68(2-3):205-221. PubMed ID: 29614633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrovascular disease associated with sickle cell pulmonary hypertension.
    Kato GJ; Hsieh M; Machado R; Taylor J; Little J; Butman JA; Lehky T; Tisdale J; Gladwin MT
    Am J Hematol; 2006 Jul; 81(7):503-10. PubMed ID: 16755569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.
    Gladwin MT; Kato GJ
    Hematology Am Soc Hematol Educ Program; 2005; ():51-7. PubMed ID: 16304359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sickle cell anemia and vascular dysfunction: the nitric oxide connection.
    Akinsheye I; Klings ES
    J Cell Physiol; 2010 Sep; 224(3):620-5. PubMed ID: 20578237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.